Overview Financials News + Filings Key Docs Ownership Insiders
|
|
MiNK Therapeutics, Inc.
|
|
| Common Size Income Statement |
|
|
|
|
Annual | Quarterly | TTM |
|
| In millions, except per share items | Jun-30-23 | Mar-31-23 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 |
| | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q |
| Revenues | | | 100.0% | 100.0% | 100.0% | |
| Cost of goods sold | | | 0.0% | 0.0% | 0.0% | |
| Gross profit | | | 100.0% | 100.0% | 100.0% | |
| Selling, general and administrative | | | 650.5% | -578.7% | | |
| Research and development | | | | | -2003289700.0% | |
| General and administrative | | | 650.5% | -578.7% | -455551700.0% | |
| Depreciation | | | | | 2028500.0% | |
| EBIT | | | 1813.2% | -439.5% | -100.0% | |
| Pre-tax income | | | -7134.8% | 4988.6% | 3021277000.0% | |
| Income taxes | | | 0.0% | 0.0% | 0.0% | |
| Net income | | | -7134.8% | 4988.6% | 3021277000.0% | |
|